KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) FCF Margin: 2011-2025

Historic FCF Margin for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to 8.60%.

  • Travere Therapeutics' FCF Margin rose 7618.00% to 8.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.48%, marking a year-over-year increase of 11738.00%. This contributed to the annual value of -101.84% for FY2024, which is 12263.00% up from last year.
  • Latest data reveals that Travere Therapeutics reported FCF Margin of 8.60% as of Q3 2025, which was up 97.51% from 4.35% recorded in Q2 2025.
  • Travere Therapeutics' 5-year FCF Margin high stood at 57.66% for Q3 2021, and its period low was -737.31% during Q4 2021.
  • For the 3-year period, Travere Therapeutics' FCF Margin averaged around -132.20%, with its median value being -74.52% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by 70,257bps in 2021, then spiked by 47,577bps in 2022.
  • Travere Therapeutics' FCF Margin (Quarterly) stood at -737.31% in 2021, then spiked by 47,577bps to -261.54% in 2022, then soared by 11,862bps to -142.92% in 2023, then surged by 9,516bps to -47.76% in 2024, then soared by 7,618bps to 8.60% in 2025.
  • Its last three reported values are 8.60% in Q3 2025, 4.35% for Q2 2025, and -51.62% during Q1 2025.